166 related articles for article (PubMed ID: 1301949)
1. An N-acetylgalactosamine-4-sulfatase mutation (delta G238) results in a severe Maroteaux-Lamy phenotype.
Litjens T; Morris CP; Robertson EF; Peters C; von Figura K; Hopwood JJ
Hum Mutat; 1992; 1(5):397-402. PubMed ID: 1301949
[TBL] [Abstract][Full Text] [Related]
2. [A novel nonsense point mutation in the arylsulfatase B gene with a severe type Maroteaux-Lamy syndrome].
Xu M
Hokkaido Igaku Zasshi; 1996 May; 71(3):359-67. PubMed ID: 8752530
[TBL] [Abstract][Full Text] [Related]
3. Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): six unique arylsulfatase B gene alleles causing variable disease phenotypes.
Isbrandt D; Arlt G; Brooks DA; Hopwood JJ; von Figura K; Peters C
Am J Hum Genet; 1994 Mar; 54(3):454-63. PubMed ID: 8116615
[TBL] [Abstract][Full Text] [Related]
4. Four novel mutant alleles of the arylsulfatase B gene in two patients with intermediate form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Voskoboeva E; Isbrandt D; von Figura K; Krasnopolskaya X; Peters C
Hum Genet; 1994 Mar; 93(3):259-64. PubMed ID: 8125475
[TBL] [Abstract][Full Text] [Related]
5. Juvenile form of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). A C-terminal extension causes instability but increases catalytic efficiency of arylsulfatase B.
Arlt G; Brooks DA; Isbrandt D; Hopwood JJ; Bielicki J; Bradford TM; Bindloss-Petherbridge CA; von Figura K; Peters C
J Biol Chem; 1994 Apr; 269(13):9638-43. PubMed ID: 8144552
[TBL] [Abstract][Full Text] [Related]
6. Identification, expression, and biochemical characterization of N-acetylgalactosamine-4-sulfatase mutations and relationship with clinical phenotype in MPS-VI patients.
Litjens T; Brooks DA; Peters C; Gibson GJ; Hopwood JJ
Am J Hum Genet; 1996 Jun; 58(6):1127-34. PubMed ID: 8651289
[TBL] [Abstract][Full Text] [Related]
7. Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation.
Kunieda T; Simonaro CM; Yoshida M; Ikadai H; Levan G; Desnick RJ; Schuchman EH
Genomics; 1995 Oct; 29(3):582-7. PubMed ID: 8575749
[TBL] [Abstract][Full Text] [Related]
8. Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). An intermediate clinical phenotype caused by substitution of valine for glycine at position 137 of arylsulfatase B.
Wicker G; Prill V; Brooks D; Gibson G; Hopwood J; von Figura K; Peters C
J Biol Chem; 1991 Nov; 266(32):21386-91. PubMed ID: 1718978
[TBL] [Abstract][Full Text] [Related]
9. Identification of the molecular defects in Spanish and Argentinian mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) patients, including 9 novel mutations.
Garrido E; Chabás A; Coll MJ; Blanco M; Domínguez C; Grinberg D; Vilageliu L; Cormand B
Mol Genet Metab; 2007; 92(1-2):122-30. PubMed ID: 17643332
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of 105 mucopolysaccharidosis type VI patients.
Karageorgos L; Brooks DA; Pollard A; Melville EL; Hein LK; Clements PR; Ketteridge D; Swiedler SJ; Beck M; Giugliani R; Harmatz P; Wraith JE; Guffon N; Leão Teles E; Sá Miranda MC; Hopwood JJ
Hum Mutat; 2007 Sep; 28(9):897-903. PubMed ID: 17458871
[TBL] [Abstract][Full Text] [Related]
11. An index case for the attenuated end of the mucopolysaccharidosis type VI clinical spectrum.
Brooks DA; Gibson GJ; Karageorgos L; Hein LK; Robertson EF; Hopwood JJ
Mol Genet Metab; 2005 Jul; 85(3):236-8. PubMed ID: 15979036
[TBL] [Abstract][Full Text] [Related]
12. Mucopolysaccharidosis type IV: N-acetylgalactosamine-6-sulfatase mutations in Tunisian patients.
Laradi S; Tukel T; Khediri S; Shabbeer J; Erazo M; Chkioua L; Chaabouni M; Ferchichi S; Miled A; Desnick RJ
Mol Genet Metab; 2006 Mar; 87(3):213-8. PubMed ID: 16378744
[TBL] [Abstract][Full Text] [Related]
13. Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase.
Litjens T; Hopwood JJ
Hum Mutat; 2001 Oct; 18(4):282-95. PubMed ID: 11668612
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy.
Karageorgos L; Harmatz P; Simon J; Pollard A; Clements PR; Brooks DA; Hopwood JJ
Hum Mutat; 2004 Mar; 23(3):229-33. PubMed ID: 14974081
[TBL] [Abstract][Full Text] [Related]
15. Mutational analysis of mucopolysaccharidosis type VI patients undergoing a phase II trial of enzyme replacement therapy.
Karageorgos L; Brooks DA; Harmatz P; Ketteridge D; Pollard A; Melville EL; Parkinson-Lawrence E; Clements PR; Hopwood JJ
Mol Genet Metab; 2007 Feb; 90(2):164-70. PubMed ID: 17161971
[TBL] [Abstract][Full Text] [Related]
16. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a Y210C mutation causes either altered protein handling or altered protein function of N-acetylgalactosamine 4-sulfatase at multiple points in the vacuolar network.
Bradford TM; Litjens T; Parkinson EJ; Hopwood JJ; Brooks DA
Biochemistry; 2002 Apr; 41(15):4962-71. PubMed ID: 11939792
[TBL] [Abstract][Full Text] [Related]
17. Maroteaux-Lamy syndrome in a large consanguineous kindred: biochemical and immunological studies.
Black SH; Pelias MZ; Miller JB; Blitzer MG; Shapira E
Am J Med Genet; 1986 Oct; 25(2):273-9. PubMed ID: 3096137
[TBL] [Abstract][Full Text] [Related]
18. Two novel mutations of the arylsulfatase B gene in two Italian patients with severe form of mucopolysaccharidosis. Mutations in brief no. 127. Online.
Villani GR; Balzano N; Di Natale P
Hum Mutat; 1998; 11(5):410. PubMed ID: 10206678
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
20. N-acetylgalactosamine-4-sulfatase: identification of four new mutations within the conserved sulfatase region causing mucopolysaccharidosis type VI.
Simonaro CM; Schuchman EH
Biochim Biophys Acta; 1995 Dec; 1272(3):129-32. PubMed ID: 8541342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
